NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia |
|
|
| Active, not recruiting | 2/3 | 640 | US, Canada, RoW | Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma | 12/20 | 12/20 | | |
EAP CHALLAH, NCT01945619: Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT |
|
|
| No Longer Available | N/A | | US | Trivirus-Specific CTLs | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, Children's Hospital Los Angeles, Duke University, Hackensack Meridian Health, New York Medical College, University of Texas Southwestern Medical Center, Children's National Research Institute, Johns Hopkins All Children's Hospital | EBV Infection, CMV Infection, Adenoviral Infection | | | | |